Medpace(US:MEDP) ZACKS·2026-01-01 00:15Company Performance - Medpace (MEDP) closed at $561.65, reflecting a -1.27% change from the previous day, underperforming the S&P 500's loss of 0.74% [1] - Prior to the latest trading session, Medpace shares had declined by 2.54%, contrasting with the Medical sector's loss of 0.8% and the S&P 500's gain of 0.79% [1] Earnings Forecast - Medpace is expected to report an EPS of $4.18, representing a 13.9% increase from the same quarter last year [2] - Revenue is forecasted to be $681.17 million, indicating a growth of 26.94% compared to the corresponding quarter of the prior year [2] Full Year Estimates - For the full year, analysts project earnings of $14.8 per share and revenue of $2.5 billion, reflecting increases of +17.18% and +18.68% respectively from the previous year [3] Analyst Estimates - Recent changes to analyst estimates for Medpace are important as they indicate shifts in near-term business trends, with positive revisions suggesting optimism about the business outlook [4] - The Zacks Rank system, which incorporates these estimate changes, currently assigns Medpace a rank of 2 (Buy) [6] Valuation Metrics - Medpace has a Forward P/E ratio of 38.45, which is a premium compared to the industry average Forward P/E of 15.5 [7] - The company also has a PEG ratio of 2.15, compared to the Medical Services industry's average PEG ratio of 1.72 [7] Industry Context - The Medical Services industry, which includes Medpace, has a Zacks Industry Rank of 165, placing it in the bottom 34% of over 250 industries [8] - Historically, the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]